VK2735
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
VK2735 is a dual GLP-1/GIP receptor agonist for rapid weight loss, marketed as an alternative to GLP-1-only drugs. Early human trials show up to 14.7% weight loss in 13 weeks and high responder rates, but the evidence base is still thin and long-term safety data are lacking. The main risk is gastrointestinal side effects, plus a theoretical thyroid tumor concern. It is not FDA-approved and circulates as unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(5)
Rapid and substantial weight loss (up to 14.7% in 13 weeks with no plateau)
HighHuman randomized trial showed up to 14.7% weight loss at 13 weeks, no plateau.
High responder rate — up to 88% of patients achieved 10% or greater weight loss
MediumPhase 2 VENTURE trial: 88% of patients lost 10%+ weight versus 4% on placebo.
Durable weight loss maintenance (over 80% of weight loss maintained 7 weeks post-dosing)
MediumSmall follow-up subset of trial participants retained most weight loss 7 weeks post-dosing.
Evidence limits
- Evidence Level
- Moderate-Strong Evidence
VK2735 has completed Phase 1 and Phase 2 trials and is now in Phase 3. The Phase 2 VENTURE trial (n=176) was a randomized, double-blind, placebo-controlled study that met all primary and secondary endpoints with up to 14.7% weight loss in 13 weeks. Results from VENTURE have been published in the journal Obesity. Both Phase 3 VANQUISH trials have completed enrollment; their efficacy and safety results remain pending.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events (nausea, vomiting, GI disturbances)
HighDehydration (from GI side effects)
ModerateLimited long-term safety data
HighThyroid C-cell tumor risk (GLP-1 class warning)
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.